Mentioned in

References in periodicals archive

With two ROS1-positive patients remaining on treatment for more than 2 years, we believe the results we announced today further distinguish repotrectinib, and are supportive of our ongoing, multi-cohort registrational Phase 2 TRIDENT-1 Study."With TPX-0046, we have demonstrated strong preclinical potency in Ba/F3 cells with the mutated KIF5B RET fusion gene and against multiple solvent front mutations that may arise from other investigational RET inhibitors and lead to treatment resistance.

Turning Point Therapeutics announced updated data on repotrectinib

[21.] Ma H, Cai Q, Lu W, Sheng ZH, Mochida S (2009) KIF5B motor adaptor syntabulin maintains synaptic transmission in sympathetic neurons.

Mechanism of Synaptic Dysfunction and How This Disruption in IGF-1 homeostasis Leads to Neurodegenerative Diseases: A Theory

* RET fusion variants KIF5B (K15:R12, K16:R12, K22:R12, K23:R12, K24:R11, K24:R8); CCDC6 (C1:R12); TRIM33 (T14:R12): Patients with mutations in this oncogene may benefit from treatment with cabozantinib or vandetinib.

Rapid biomarker testing for improved clinical decision-making in non-small cell lung cancer

For RET-positive patients, kinesin family member 5B (KIF5B) and coiled-coil domain containing 6 (CCDC6) were the partners identified.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients

Ambrosio, "Diabetes induces changes in KIF1A, KIF5B and dynein distribution in the rat retina: Implications for axonal transport," Experimental eye Research, vol.

Elevated Glucose and Interleukin-1[beta] Differentially Affect Retinal Microglial Cell Proliferation

Ferreira, "The docking of kinesins, KIF5B and KIF5C, to ran-binding protein 2 (RanBP2) is mediated via a novel RanBP2 domain," The Journal of Biological Chemistry, vol.

Chimeric Genes in Deletions and Duplications Associated to Intellectual Disability

Elvas et al., "Diabetes alters KIF1A and KIF5B motor proteins in the hippocampus," PLoS ONE, vol.

The protective effects of insulin and natural honey against hippocampal cell death in streptozotocin-induced diabetic rats

Recent research has also revealed that RET and KIF5B gene fusion (gene mutation) occurs in some lung cancer patients, which means that RET tyrosine kinase inhibitors may potentially be used in the treatment of lung cancer patients with this gene mutation.

Eisai Receives Orphan Drug Designation for Anticancer Agent Lenvatinib in Japan

(12) In addition to EML4, less common fusion partners have been described, including TRK-fused gene (TFG), kinesin light chain 1 (KLC1), and kinesin family member 5B (KIF5B), although the clinical relevance of the different fusion partners is unknown.

Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization

Furthermore, in addition to EML4, other ALK fusion partners have been reported, such as TRK-fused gene (TGF), kinesin family member 5B (KIF5B), and kinesin light chain 1 (KLC1).

Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?

As with ALK and ROS1 rearrangements, RET is activated by rearrangements that fuse the tyrosine kinase domain of RET with coiled-coil dimerization domains of one of a variety of recurring partner genes, including KIF5B (the most common, at 90%), (64,72,73) CCDC6, (65,74) NCOA (4,62) and TRIM33.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology